HealthDay News — For patients with lentigo maligna (LM) in-situ melanoma, topical imiquimod has a pathological complete regression (pCR) rate of 37%, according to a study published online October 6 in ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Five years after treatment, results showed a freedom ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback